Target organ damage: How to detect it and how to treat it?

Journal of Hypertension

Volumn 27, Issue SUPPL. 3, 2009, Pages

  Waebera, Bernard ^a   De La Sierra, Alejandro ^b   Ruilope, Luis M ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Albuminuria; Antihypertensive therapy; Atherosclerosis; Hypertension; Left ventricular hypertrophy; Nephropathy; Target organ damage

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LABORATORY TEST; MICROALBUMINURIA; ORGAN INJURY; PRIORITY JOURNAL; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING TEST; TARGET ORGAN DAMAGE; CHRONIC DISEASE; KIDNEY DISEASE; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; RISK FACTORS;

EID: 69149088064     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000356767.24507.8d     Document Type: Review

References (46)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
2. Staessen JA, Wang JG, Thijs L. What can be expected from optimal blood pressure control? J Hypertens 2003; 21 (Suppl.):3-9.
3. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States. Part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005; 329:292-305.
4. Houston MC, Basile J, Bestermann WH, Egan B, Lackland D, Hawkins RG, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci 2005; 329:276-291.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
6. Frohlick ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
7. Ruilope LM, Rodicio JL. Renal participation in cardiovascular risk in essential hypertension. Blood Pressure 2001; 10:322-326.
8. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169. (Pubitemid 37337595)
9. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21:1213-1220.
10. Ashley EA, Raxwal V, Froelicher V. An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. Progr Cardiovasc Dis 2001; 44:55-67.
11. Alfakih K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006; 24:1223-1230.
12. Larsen CT, Dahlin J, Blackburn H, Scharling H, Appleyard M, Sigurd B, Schnohr P. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study. Eur Heart J 2002; 23:315-324.
13. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15:43-51.
14. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899. (Pubitemid 37315486)
15. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25:417-423.
16. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000; 35:13-18. (Pubitemid 30054230)
17. Devereux RB, Roman MJ. Ultrasonic techniques for the evaluation of hypertension. Curr Opin Nephrol Hypertens 1994; 3:644-651.
18. Crouse JR III. Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art. J Lipid Res 2006; 47:1677-1699.
19. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432-1437.
20. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
21. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
22. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-386.
23. McDermott MM. Ankle brachial index as a predictor of outcomes in peripheral arterial disease. J Lab Clin Med 1999; 133:33-40.
24. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 1997; 45:1472-1478.
25. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358:1134-1140.
26. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287:1153-1159.
27. Fuchs FD, Maestri MK, Bredemeier M, Cardozo SE, Moreira FC, Wainstein MV, et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. J Hum Hypertens 1995; 9:547-551.
28. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1):S1-S266.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
31. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
32. Redon J, Cea-Calvo L, Lozano JV, Fernández-Pérez C, Navarro J, Bonet A, Gonzá lez-Esteban J. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24:663-669.
33. Gerber LM, JohnstonK, Alderman MH. Assessmentof a new dipstick testin screening for microalbuminuria in patients with hypertension. Am J Hypertens 1998; 11:1321-1327.
34. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.
35. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31:673-689.
36. Weir MR. Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. J Clin Hypertens 2004; 6:134-141.
37. Brunner H, Cockcroft JR, Deanfield J, Doald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:233-246. (Pubitemid 40279622)
38. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int 2004; 92 (Suppl.):42-44.
39. Rosa TT, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens 2000; 18:645-654.
40. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223-228.
41. Bianchi S, Bigazzi R, Quinones Galvan A, Muscelli E, Baldari G, Pecori N, et al. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26:789-795.
42. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526.
43. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4:393-404.
44. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
45. Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabet 2005; 42 (Suppl. 1):33-41.
46. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604-615.